| Record ID | harvard_bibliographic_metadata/ab.bib.11.20150123.full.mrc:780302273:1673 |
| Source | harvard_bibliographic_metadata |
| Download Link | /show-records/harvard_bibliographic_metadata/ab.bib.11.20150123.full.mrc:780302273:1673?format=raw |
LEADER: 01673nam a2200385 a 4500
001 011878396-3
005 20090421121548.0
008 081113s2008 dcua b 000 0 eng
010 $a 2008049681
020 $a9780844742779
020 $a0844742775
035 0 $aocn275863635
040 $aDNLM/DLC$cDLC
042 $apcc
043 $an-us---
050 00 $aHD9666.6$b.V47 2008
060 10 $aQV 733.1$bV541p 2008
082 00 $a338.4/361510973$222
100 1 $aVernon, John A.
245 10 $aPharmaceutical price regulation :$bpublic perceptions, economic realities, and empirical evidence /$cJohn A. Vernon and Joseph H. Golec.
260 $aWashington, D.C. :$bThe AEI Press,$cc2008.
300 $aviii, 72 p. :$bill. ;$c22 cm.
504 $aIncludes bibliographical references (p. 65-69).
505 0 $aR&D investment in new drugs : how it works, and how it is harmed by price controls -- Government price regulation and the impact on pharmaceutical R&D spending -- Government intervention and the threats to drug R&D -- Summary and conclusions : why public policy must recognize the trade-off between lower prices today and life-saving medicines tomorrow.
650 0 $aPharmaceutical industry$xGovernment policy$zUnited States.
650 0 $aDrugs$xPrices$xLaw and legislation$zUnited States.
650 12 $aFees, Pharmaceutical$xlegislation & jurisprudence.
650 22 $aCosts and Cost Analysis.
650 22 $aDrug Industry$xeconomics.
650 22 $aGovernment Regulation.
650 22 $aResearch$xeconomics.
700 1 $aGolec, Joseph.
710 2 $aAmerican Enterprise Institute for Public Policy Research.
988 $a20090227
906 $0OCLC